Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).
- Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).
- Dr. Dicpinigaitis is board-certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine.
- “We are very pleased that Dr. Dicpinigaitis has joined Algernon as a medical advisor,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
- At the time, Gefapixant had interim data from a Phase 2b dose-escalation study in refractory chronic cough.